Hantavirus pulmonary syndrome in Texas: An update covering years 1993 through 2016
Abstract
Background: Hantavirus pulmonary syndrome continues to occur sporadically in Texas. Rivers and coworkers published a summary of cases identified between 1993 and 2006. This report updates the information on Hantavirus pulmonary syndrome cases identified between 2007 and 2016 to determine whether or not there are differences in clinical presentation or outcomes.
Methods: The Texas Department of State Health Services collects information on the Hantavirus pulmonary syndrome using the Centers for Disease Control and Prevention, Special Pathogens Branch case report form (OMB No.0920-0090). This form collects demographic information, patient exposure information, timeline, clinical information, laboratory tests, and outcomes.
Results: This report summarizes information from the Texas Department of State Health Services on 45 cases with Hantavirus pulmonary syndrome reported between 1993 and 2016. Most patients were men and were non-Hispanic white or Hispanics. Laboratory tests revealed leukocytosis, an increased percentage of neutrophil bands, hemoconcentration, thrombocytopenia, and variable acute kidney injury. The case fatality rate was 31%. Since 2007, the case fatality rate has decreased. The cases remain clustered in the Northwest Texas (Public Health Region 1).
Summary: Hantavirus pulmonary syndrome continues to occur sporadically in Texas. The clinical presentation has not changed since 1993, but outcomes appear to be improving. Public health efforts need to focus on public education to reduce the risk of exposure.
Keywords: Hantavirus pulmonary syndrome, Texas, laboratory tests, outcomes
Downloads
References
Duchin JS, Koster FT, Peters CJ, et al. Hantavirus pulmonary
syndrome: a clinical description of 17 patients with a newly
recognized disease. The Hantavirus Study Group. N Engl J
Med 1994;330:949–55.
Khan AS, Khabbaz RF, Armstrong LR, et al. Hantavirus
pulmonary syndrome: the first 100 US cases. J Infectious
dDisease 1996;173:1297–303.
Rivers MN, Alexander JL, Rohde RE, Pierce JR. Hantavirus
pulmonary syndrome in Texas: 1993-2006. South Med J
;102:36–41.
de St. Maurice A, Ervin E, et al. Exposure chracteristics of
Hantavirus pulmonary syndrome patients, United States,
-2015. Emerg Infect Dis 2017;733–739.
Calisher CH, Mills JN, Root JJ, Doty JB, Beaty BJ. The relative
abundance of deer mice with antibody to Sin Nombre
virus corresponds to the occurrence of hantavirus pulmonary
syndrome in nearby humans. Vector Borne Zoonotic
Dis 2011;11:577–82.
Brocato RL, Hammerbeck CD, Bell TM, Wells JB, Queen
LA, Hooper JW. A lethal disease model for hantavirus
pulmonary syndrome in immunosuppressed Syrian hamsters
infected with Sin Nombre virus. J Virol 2014;88:
–9.
Safronetz D, Prescott J, Feldmann F, et al. Pathophysiology
of hantavirus pulmonary syndrome in rhesus macaques.
Proc Natl Acad Sci U S A 2014;111:7114–9.
Safronetz D, Falzarano D, Scott DP, Furuta Y, Feldmann
H, Gowen BB. Antiviral efficacy of favipiravir against
two prominent etiological agents of hantavirus pulmonary
syndrome. Antimicrob Agents Chemother 2013;57:
–80.
Haese N, Brocato RL, Henderson T, et al. Antiviral Biologic
Produced in DNA Vaccine/Goose Platform Protects
Hamsters Against Hantavirus Pulmonary Syndrome When
Administered Post-exposure. PLoS Negl Trop Dis 2015;
:e0003803.
Calisher CH, Sweeney W, Mills JN, Beaty BJ. Natural history
of Sin Nombre virus in western Colorado. Emerg Infect
Dis 1999;5:126–34.
